Replacement of the C6oRF66 assembly factor (NDUFAF4) restores complex I activity in patient cells

Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 124-134

  Marcus, Dana ^a   Lichtenstein, Michal ^a   Saada, Ann ^b   Lorberboum Galski, Haya ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE) ASSEMBLY FACTOR 4; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; C6ORF66 GENE; CELL ACTIVITY; CELL COUNT; COMPLEX I DEFICIENCY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPLACEMENT; ESCHERICHIA COLI; GENE; GENE DELIVERY SYSTEM; GENE FUSION; GENE PRODUCT; GENE TARGETING; HUMAN; HUMAN CELL; MITOCHONDRION; OPEN READING FRAME; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

CALMODULIN-BINDING PROTEINS; CELLS, CULTURED; ELECTRON TRANSPORT COMPLEX I; FIBROBLASTS; GENE PRODUCTS, TAT; HUMANS; MITOCHONDRIAL DISEASES; RECOMBINANT FUSION PROTEINS;

EID: 84878780818     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00343     Document Type: Article

References (39)

1. Koopman WJ, Willems PH, Smeitink JA. (2012) Monogenic mitochondrial disorders. N. Engl. J. Med. 366:1132-1141
2. Thorburn DR. (2004) Mitochondrial disorders: prevalence, myths and advances. J. Inherit. Metab. Dis. 27:349-362
3. Balsa E, et al. (2012) NDUFA4 is a subunit of complex IV of the mammalian electron transport chain. Cell Metab. 16:378-386
4. Calvo SE, et al. (2010) High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat. Genet. 42:851-858
5. Janssen R, Smeitink J, Smeets R, van Den Heuvel L. (2002) CIA30 complex I assembly factor: a candidate for human complex I deficiency? Hum. Genet. 110:264-270
6. Ogilvie I, Kennaway NG, Shoubridge EA. (2005) A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. J. Clin. Invest. 115:2784-2792
7. Zurita Rendon O, Shoubridge EA. (2012) Early complex I assembly defects result in rapid turnover of the ND1 subunit. Hum. Mol. Genet. 21:3815-3824
8. Lazarou M, McKenzie M, Ohtake A, Thorburn DR, Ryan MT. (2007) Analysis of the assembly profiles for mitochondrial- and nuclear-DNAencoded subunits into complex I. Mol. Cell. Biol. 27:4228-4237
9. McKenzie M, Ryan MT. (2010) Assembly factors of human mitochondrial complex I and their defects in disease. IUBMB Life. 62:497-502
10. Haack TB, et al. (2010) Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat. Genet. 42:1131-1134
11. Fassone E, et al. (2010) FOXRED1, encoding an FAD-dependent oxidoreductase complex-Ispecific molecular chaperone, is mutated in infantile-onset mitochondrial encephalopathy. Hum. Mol. Genet. 19:4837-4847
12. Nouws J, et al. (2010) Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I. Cell Metab. 12:283-294
13. Gerards M, et al. (2011) Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. Brain. 134:210-219
14. Saada A, et al. (2012) Combined OXPHOS complex I and IV defect, due to mutated complex I assembly factor C20ORF7. J. Inherit. Metab. Dis. 35:125-131
15. Rapoport M, Saada A, Elpeleg O, Lorberboum- Galski H. (2008) TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol. Ther. 16:691-697
16. Karp CM, Shukla MN, Buckley DJ, Buckley AR. (2007) HRPAP20: a novel calmodulin-binding protein that increases breast cancer cell invasion. Oncogene. 26:1780-1788
17. Brady RO. (2006) Enzyme replacement for lysosomal diseases. Annu. Rev. Med. 57:283-296
18. Brady RO, Schiffmann R. (2004) Enzymereplacement therapy for metabolic storage disorders. Lancet Neurol. 3:752-756
19. Green M, Loewenstein PM. (1988) Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55:1179-1188
20. Luft FC. (2003) Transducing proteins to manipulate intracellular targets. J. Mol. Med. (Berl.). 81:521-523
21. Futaki S, et al. (2001) Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276:5836-5840
22. Kabouridis PS. (2003) Biological applications of protein transduction technology. Trends Biotechnol. 21:498-503
23. Frankel AD, Pabo CO. (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1189-1193
24. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:1569-1572
25. Guo X, Hutcheon AE, Zieske JD. (2004) Transduction of functionally active TAT fusion proteins into cornea. Exp. Eye Res. 78:997-1005
26. Del Gaizo V, MacKenzie JA, Payne RM. (2003) Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. 80:170-180
27. Rapoport M, Salman L, Sabag O, Patel MS, Lorberboum-Galski H. (2011) Successful TATmediated enzyme replacement therapy in a mouse model of mitochondrial E3 deficiency. J. Mol. Med. (Berl.). 89:161-170
28. Golubitzky A, et al. (2011) Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound. PLoS One. 6:e26883
29. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34:267-273
30. Eckert A, Schulz KL, Rhein V, Gotz J. (2010) Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol. Neurobiol. 41:107-114
31. Winklhofer KF, Haass C. (2010) Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta. 1802:29-44
32. Leifert JA, Harkins S, Whitton JL. (2002) Fulllength proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther. 9:1422-1428
33. Toro A, Grunebaum E. (2006) TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J. Clin. Invest. 116:2717-2726
34. Suhorutsenko J, et al. (2011) Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug. Chem. 22:2255-2262
35. Vyas PM, Payne RM. (2008) TAT opens the door. Mol. Ther. 16:647-648
36. Rayapureddi JP, Tomamichel WJ, Walton ST, Payne RM. (2010) TAT fusion protein transduction into isolated mitochondria is accelerated by sodium channel inhibitors. Biochemistry. 49:9470-9479
37. Shokolenkoa IN, Alexeyevb MF, LeDouxa SP, Wilson GL. (2005) TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells. DNA Repair (Amst.). 4:511-518
38. Foltopoulou PF, Tsiftsoglou AS, Bonovolias ID, Ingendoh AT, Papadopoulou LC. (2010) Intracellular delivery of full length recombinant human mitochondrial L-Sco2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient's primary cells. Biochim. Biophys. Acta. 1802:497-508
39. Vyas PM, et al. (2012) A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model. Hum. Mol. Genet. 21:1230-1247.